A number of studies have indicated that neuropeptide Y (NPY) is a central regulator of the gonadotropic axis, and the Y1 receptor was initially suggested to be implicated. As at least five different NPY receptor subtypes have now been characterized, the aim of the present study was to reinvestigate the pharmacological profile of the receptor(s) mediating the inhibitory action of NPY on LH secretion by using a panel of NPY analogs with different selectivity toward the five NPY receptor subtypes. When given intracerebroventricularly (icv) to castrated rats, a bolus injection of native NPY (0.7-2.3 nmol) dosedependently decreased plasma LH. Peptide YY (PYY; 2.3 nmol) was as potent as NPY, suggesting that the Y3 receptor is not implicated. Confirming previous data, the mixed Y1, Y4, and Y5 agonist [Leu 31 ,Pro 34 ]NPY (0.7-2.3 nmol) inhibited LH release with potency and efficacy equal to those of NPY. Neither the selective Y2 agonist C2-NPY (2.3 nmol) nor the selective Y4 agonist rat pancreatic polypeptide affected plasma LH, excluding Y2 and Y4 subtypes for the action of NPY on LH secretion. The mixed Y4-Y5 agonist human pancreatic polypeptide (0.7-7 nmol) as well as the mixed Y2-Y5 agonist PYY 3-36 (0.7-7 nmol) that displayed very low affinity for the Y1 receptor, thus practically representing selective Y5 agonists in this system, decreased plasma LH with potency and efficacy similar to those of NPY, indicating that the Y5 receptor is mainly involved in this inhibitory action of NPY on LH secretion. ]NPY, a selective, but weak, Y5 agonist, also inhibited plasma LH at a dose of 7 nmol. Furthermore, the inhibitory action of NPY (0.7 nmol) on LH secretion could be fully prevented, in a dose-dependent manner (6 -100 g, icv), by a nonpeptidic Y5 receptor antagonist. This antagonist (60 g, icv) also inhibited the stimulatory action of NPY (0.7 nmol) on food intake. ]PYY binding to rat brain membrane homogenates in the presence of the Y1 receptor antagonist BIBP3226, a binding assay system that was described as being highly specific for Y5-like receptors. With the exception of ]NPY, all analogs able to inhibit LH secretion were also able to stimulate food intake. Taken together, these results indicate that the Y5 receptor is involved in the negative control by NPY of the gonadotropic axis. (Endocrinology 140: 4046 -4055, 1999) N EUROPEPTIDE Y (NPY) is a 36-amino acid peptide belonging to the pancreatic peptide (PP) family. In mammals, this family consists of PP, peptide YY (PYY) of gastrointestinal origin, and NPY (1). Although PP and PYY are primarily located in the periphery, NPY is predominantly located within neurons of the central and sympathetic nervous systems (2-4). In the rat, five NPY receptor subtypes (Y1-Y5) have been characterized on the basis of different pharmacological profiles and/or cloning (5, 6). A sixth subtype (Y6) has been cloned from mice (7, 8) , but the existence of this subtype in rats remains to be proven. The existence of additional NPY receptor subtypes has been postulated. NPY receptor subtypes are members of the seven-transmembrane domain, G protein-coupled receptors associated with inhibition of adenylate cyclase.
]PYY binding to rat brain membrane homogenates in the presence of the Y1 receptor antagonist BIBP3226, a binding assay system that was described as being highly specific for Y5-like receptors. With the exception of ]NPY, all analogs able to inhibit LH secretion were also able to stimulate food intake. Taken together, these results indicate that the Y5 receptor is involved in the negative control by NPY of the gonadotropic axis. (Endocrinology 140: 4046 -4055, 1999) N EUROPEPTIDE Y (NPY) is a 36-amino acid peptide belonging to the pancreatic peptide (PP) family. In mammals, this family consists of PP, peptide YY (PYY) of gastrointestinal origin, and NPY (1) . Although PP and PYY are primarily located in the periphery, NPY is predominantly located within neurons of the central and sympathetic nervous systems (2) (3) (4) . In the rat, five NPY receptor subtypes (Y1-Y5) have been characterized on the basis of different pharmacological profiles and/or cloning (5, 6) . A sixth subtype (Y6) has been cloned from mice (7, 8) , but the existence of this subtype in rats remains to be proven. The existence of additional NPY receptor subtypes has been postulated. NPY receptor subtypes are members of the seven-transmembrane domain, G protein-coupled receptors associated with inhibition of adenylate cyclase.
The highest concentrations of NPY in the brain are found within several hypothalamic nuclei that regulate a variety of neuroendocrine and autonomic functions (9) , and one of the first reported actions of NPY actually involved studies of the endocrine and eating behavior responses to human PP (hPP) and NPY (10 -15) . In these original studies, it was shown that central administration of NPY stimulated food consumption (12) (13) (14) (15) , inhibited sexual behavior (14) , and modulated the activity of the gonadotropic axis (10, 11, 15) . In contrast to the straightforward action of NPY on feeding behavior, the regulation of the gonadotropic axis by this neuropeptide is rather complex. It was shown that NPY can stimulate LH release in sex steroid-primed ovariectomized rats after central administration (10, 15) . In contrast, in castrated animals, central administration of NPY produced a striking inhibition of LH release, as seen in rats (10, 16, 17) , rabbits (18) , and nonhuman primates (19) . Furthermore, in both male and female intact rats, chronic intracerebroventricular (icv) infusion of NPY led to a profound inhibition of the gonadotropic axis (20, 21) and prolongation of sexual immaturity (22) . Based on the observation that this dual action of NPY on the gonadotropic axis could be reproduced by the Y1 agonist [Leu 31 ,Pro 34 ]NPY, but not by the Y2 agonist NPY , both the stimulatory and inhibitory actions of NPY were postulated to be mediated by the NPY Y1 receptor subtype (21, 23 (25, (27) (28) (29) . We also examined the effect of a selective Y5 antagonist (30) . Finally, because several reports have led to the proposal that feeding behavior and activity of the gonadotropic axis are linked, and that NPY may be pivotal in this relationship (21, 31) , we also evaluated the effects of these analogs and the Y5 antagonist on food intake. Together with literature data and binding studies performed in the rat brain, these in vivo results have indicated that both inhibition of the gonadotropic axis and stimulation of food intake by NPY are predominantly mediated by the Y5 receptor subtype.
Materials and Methods Animals
Male Sprague Dawley rats (200 -220 g) obtained from Iffa Credo (L'Arbresle, France) were fed standard laboratory chow ad libitum and kept on a 12-h light, 12-h dark (lights on, 0700 -1900 h) schedule in a temperature-and humidity-controlled room. Animal care was performed according to protocols reviewed by the University of Geneva School of Medicine ethical committee for animal experimentation and approved by the State of Geneva Veterinary Office.
Materials
Porcine (p) NPY, hPYY 34 ]PYY using the chloramine-T method as previously described (32) , and the specific activity was assumed to be a theoretical value (2000 Ci/mmol).
Surgical procedure
Castration and implantation of intracerebroventricular cannula. Rats were weighed and anesthetized with ketamine/xylazine (3 and 7 mg/kg, ip, respectively). An incision of the skin was made in the middle of the scrotum, and the testicles and epididymis were exposed. The testicles were separated from the epididymis and cut-off after ligation of the artery. Cannulas, aimed at the right lateral ventricle, were placed 1 mm posterior and 2 mm lateral to bregma and extended 2 mm below the outer surface of the skull. Rats were allowed to recover for 7 days, as described previously (20) .
Implantation of jugular catheter. Under the same anesthetic, the ventral side of the throat was shaved, and an incision was made down the center of the throat. The right jugular vein was exposed and cannulated using polythene tubing (OD, 1.0 mm) connected to a medical grade silicone tubing (OD, 0.94 mm; silicone side in the jugular vein). The tubing was secured, and the polythene side was externalized through an incision made on the dorsal side of the neck. The catheter was rinsed with 300 l Ringer's solution containing 0.1% heparin. Rats were allowed to recover for at least 24 h in individual cages, with food and water available ad libitum.
Experimental procedure
All experiments were carried out between 14 -18 h. Before the start of the experiments, rats were weighed and placed in individual cages with a preweighed amount of food. The different analogs, dissolved in sterile distilled water, were injected (icv) in a volume of 5 l. The Y5 antagonist, dissolved in sterile distilled water slightly acidified by acetic acid 2% (15% of the total volume, pH 6.5), was injected (icv) 15 min before NPY. Blood samples (200 -250 l) were removed immediately before and 15, 30, 60, 90, and 120 min after central injections. Each blood sample was replaced with an equivalent volume of Ringer's solution containing 0.1% heparin. Plasma was extracted and stored at Ϫ20 C until determination of LH by RIA. Food intake was measured after 2 h. At the end of the study, the rats were anesthetized, and an icv injection of 5 l methylene blue dye was made. Animals were then killed by decapitation, and the brain was inspected for uniform and complete spread of the dye in the lateral ventricle. Data from any subject with inadequate spread of the marker were discarded.
Determination of plasma LH levels
LH was determined by RIA using reagents prepared by Dr. A. F. Parlow and provided by the NIDDK (Bethesda, MD), with the exception of the second antiserum. NIDDK antirat LH S11 serum was used. Values were expressed in terms of the RP-1 reference standard. For each experiment, all plasma samples (vehicle control and tested analog) were measured in the same RIA.
Ligand binding assays
Membranes were prepared as previously described (32) . Briefly, rats were killed by decapitation, and their brains rapidly removed and homogenized in Krebs-Ringer phosphate (KRP) buffer at pH 7.4 of the following composition: NaCl (120 mm), KCl (4.7 mm), CaCl 2 (2.2 mm), KH 2 PO 4 (1.2 mm), MgSO 4 (1.2 mm), dextrose (5.5 mm), and NaHCO 3 (25 mm) using a Brinkmann Instruments, Inc., Polytron (Westbury, NY; at setting 6 for 15-20 sec). Homogenates were centrifuged at 49,000 ϫ g for 20 min, supernatants were discarded, and pellets were washed, resuspended, and recentrifuged twice.
All binding assays were initiated by adding 100 l of membrane preparations in a final volume of 500 l KRP containing 0.1% (wt/vol) BSA, 0.05% (wt/vol) bacitracin, 125 Ϫ6 m. All binding assays were performed in the absence or presence of 1 m BIBP3226 to block the Y1 receptor subtype. Nonspecific binding was determined in the presence of 1 m pNPY. After 2 h, the binding reaction was terminated by rapid filtration through Schleicher and Schuell no. 32 glass filters (previously soaked in 1.0% polyethyleneimine) using a cell harvester filtering apparatus (Brandel Instruments, Gaithersburg, MD). Filters were rinsed three times with 3 ml cold KRP, and the radioactivity remaining on filters was quantified using a ␥-counter with 85% efficiency (Packard Instruments, Downers Grove, IL).
All binding experiments were repeated three times, each in triplicate, and results are expressed as a percentage of the specific binding, representing the mean Ϯ sem. IC 50 values (i.e. concentration of unlabeled peptide required to compete for 50% of specific binding of the radioligand) of the various peptides and Y5 antagonist were calculated from the competition binding assays data using GraphPad software (GraphPad Software, Inc., San Diego, CA).
Statistical analysis
The effect of each NPY analog on plasma concentrations of LH was analyzed by one-way ANOVA followed by Dunnett's t test to examine the differences between each postinjection time point and the preinjection basal value. The effects of NPY analogs on food intake were analyzed by a one-way ANOVA followed by Dunnett's t test. For the study with the Y5 antagonist, one-way ANOVA followed by StudentsNewman-Keuls test were performed.
Results

NPY-induced inhibition of LH release in the castrated rat: dose-response study
An icv bolus injection of NPY (0.07-7 nmol) produced a dose-related inhibition of LH secretion, as seen from plasma LH levels measured during the 120-min period after NPY injection (Fig. 1) . The lowest NPY dose tested (0.07 nmol) was ineffective. For the other four doses, a significant decrease (P Ͻ 0.05) was first observed after 30 min. Minimum LH values were reached after 30 min for the 0.23-nmol dose and at later times with increasing doses. With the highest dose (7 nmol), plasma LH levels were still decreasing after 120 min. 
Effects of NPY analogs on plasma LH levels in the castrated rat
Effects of a Y5 receptor antagonist (Y5-ant) on NPY-induced inhibition of plasma LH levels
The Y5 antagonist was tested in the presence of native NPY in the castrated rat. When given as a bolus icv injection (60 g) 15 min before NPY (0.7 nmol), Y5-ant fully inhibited the lowering effect of NPY on plasma LH levels without affecting basal plasma LH levels (Fig. 4) . The antagonistic action of Y5-ant was dose related; a significant inhibition was reached with the dose equal to or greater than 60 g, and full reversion was achieved at a dosage of 100 g (Fig. 5) .
Binding of NPY, NPY analogs, and the Y5 receptor antagonist to rat brain membrane homogenates
To evaluate the affinities at the Y1 and Y5 receptors of the NPY analogs and the Y5 antagonist, competition of the binding of 125 (Table 1) . Both hPP (known as a mixed Y4-Y5 specific analog) and PYY (known as a mixed Y2-Y5 specific analog) had a very weak affinity for Y1-like activity and a strong binding capacity for the Y5-like type of binding ( Table  1 ). The Y2-selective NPY analog C2-NPY and the Y4-selective peptide rPP displayed very weak activity for both types of binding. Finally, the nonpeptidic Y5 receptor antagonist described by Novartis clearly induced strong inhibition of the Y5-like type of binding and no inhibition of the Y1-like type of activity in this competitive binding system (Table 1 ). In addition, this compound was found to have no affinity for Y1 receptors in intact human neuroblastoma SK-N-MC cells (IC 50 , Ͼ1000 nm).
Effects of NPY and NPY analogs on food intake in the castrated rat
Food intake induced by bolus injection of NPY or NPY analogs was assessed during 2 h in the castrated rats used for the study on LH secretion. Significant stimulation of food intake was observed for all NPY analogs able to decrease LH secretion, except for ]NPY at the doses tested (0.7-7 nmol) was unable to stimulate food intake.
Effects of the Y5 receptor antagonist (Y5-ant) on NPYinduced stimulation of food intake in the castrated rat
The Y5 antagonist was able, when given as an icv bolus injection of 60 g, to fully inhibit the stimulatory effect of NPY (0.7 nmol) on 2-h food consumption. Y5-ant alone (60 g) had no effect on food intake ( Table 2) .
Discussion
Early studies of NPY action demonstrated that a bolus injection into the lateral ventricle of rats (recognized as central, or icv, injection) could induce a robust feeding response in satiated rats (12) (13) (14) (15) , a reduction in sexual behavior (14) , and a dual effect on LH secretion (15) . Indeed, bolus injection of NPY elicited a modest increase in LH secretion in intact males and gonadectomized, sex steroid-primed females (15) , whereas such a bolus injection induced a striking, dose- dependent decrease in plasma LH in castrated rats (10, 17) . The physiological significance of the stimulatory effect of NPY in sex steroid-intact animals has been reviewed extensively, indicating that in several situations, NPY clearly provides an excitatory signal for LH release (31) . The significance of the inhibitory effect of bolus NPY injection on LH and FSH secretion was greatly highlighted by the demonstration that chronic, 1-week central infusion of NPY into the lateral ventricle fully inhibited the gonadotropic axis in intact female rats, with a collapse of estrous cyclicity (20) and delayed sexual maturation in female rats (22, 33) , and a spectacular inhibition of testicular function in male rats (21) . Interestingly, chronic, central infusion of NPY produced at least three different effects: 1) unabated increase in food intake leading to obesity, 2) suppression of gonadotropin secretion (21, 34) , and 3) suppression of GH secretion, with low insulin-like growth factor I secretion as a consequence (21) . Even if these different actions of NPY appear to be coordinated, it is not clear whether they are mediated by the same NPY receptor subtype(s). To reinvestigate NPY receptor selectivity for the action on LH secretion, the most simple model was chosen: the inhibitory action of central, bolus NPY injections at different doses on LH secretion in castrated male rats that yields most precise answers in terms of pharmacological action.
The panel of NPY agonists used in this study was chosen because their specificities toward the different Y receptors are well documented by numerous studies published over several years (for review, see Refs. 6 and 7). Recently, their specificities were further established by functional studies of the specific Y receptor, expressed in stable cell lines such as, for example, the analysis proposed by Gerald et al. (25) . Also, the specificities of several NPY agonists or antagonists for the Y1 and Y5 receptor subtypes in rat brain were reevaluated recently by two of us, using a paradigm of binding competition of [ 125 I][Leu 31 ,Pro 34 ]PYY to rat brain membrane homogenates in the absence or presence of 1 mm BIBP3226, a highly specific Y1 receptor antagonist (35) , that allows clear discrimination between Y1 and Y5 receptor binding specificities (29) .
In the present study we confirmed the clear dose-dependent inhibitory action of centrally administered NPY on LH secretion in the male castrated rat, first described by Kalra and Crowley in the eighties (15) . The involvement of the Y2 receptor subtype for this NPY action on LH secretion was eliminated in another study published by Kalra et al. in 1992 (23) and by us, as chronic administration of NPY had no effect on the pituitary-testicular axis of male rats (21) . Consistent with this, C2-NPY, a specific Y2 analog, had no effect on LH secretion in the castrated rat in the present study. Receptor subtype Y4 could be eliminated as well, as the specific Y4 receptor agonist rPP was inactive. Furthermore, PYY, which binds only poorly to the Y3 receptor subtype (28), was as active as NPY to inhibit LH secretion, making it unlikely that the Y3 receptor subtype could be involved. At this point, only receptor subtypes Y1 and Y5 were still candidates for the mediation of the action of NPY on LH secre- Each value represents the mean Ϯ SEM for the quantity of food ingested during 2 h. The number of rats per group is indicated in parentheses.
a Significantly different from vehicle-injected rats. b Significantly different from NPY-injected rats, as determined by Student-Newman-Keuls test (P Ͻ 0.001).
tion. Three analogs were particularly useful to demonstrate that NPY action on LH secretion in the castrated rat is predominantly mediated by the Y5 receptor subtype: PYY 3-36 , a mixed Y2 and Y5 agonist; hPP, a mixed Y4 and Y5 agonist; and [d-Trp 32 ]NPY, a weak but selective Y5 ligand (25, (27) (28) (29) . Those three analogs were found to inhibit LH secretion with potency and efficacy similar to those of NPY despite very weak affinity for the Y1 receptor subtype. Taken together, the data obtained with PYY hPP, ]NPY indicated that the Y5, rather than the Y1, receptor subtype is involved in mediation of the inhibitory action of NPY on LH secretion in the castrated rat. These data make it very unlikely that the Y1 receptor subtype is still involved, although this possibility cannot be completely eliminated at this point. For such a demonstration, a pure Y1 receptor agonist or a powerful, selective, and nontoxic Y1 receptor antagonist is still needed. There are unfortunately no Y1 antagonists that could be used for such a demonstration. It is known that the nonpeptidic BIBP3226 (35) and the more recently available BIBO3304 (36) are specific Y1 antagonists, but their use in in vivo models is limited due to their neurotoxicity. In a preliminary experiment performed in our laboratory, BIBO3304 (10 g/rat), coinjected centrally (icv) with NPY (3 g/rat), was unable to inhibit the inhibitory effect of NPY on LH secretion (data not shown). When tested at a larger concentration (30 g/rat), BIBO3304 clearly induced neurotoxic manifestations, thus preempting the use of this antagonist at meaningful concentrations. 1229U91 (GW1229) is another Y1 antagonist that could have been used in our model (37) . However, this peptidic NPY analog is known to display high binding affinity in vitro for both Y1 and Y4 receptors and weak affinity for Y2 and Y5 receptor subtypes (38) . It is therefore very difficult to make any meaningful demonstration of Y1 specificity by using such a compound.
We synthesized a Y5 antagonist that was described as having an IC 50 of 2.3 nm for the cloned Y5 receptor (30) . In our hands, this nonpeptidic receptor antagonist was found to be highly specific to displace the ]PYY/BIBP3226-insensitive sites in the rat brain and to display no binding to Y1 receptors of neuroblastoma SK-N-MC cells, thus confirming its Y5 specificity. This Y5 receptor antagonist, when administered icv, with no apparent toxicity problem, fully reversed, in a dose-dependent manner, the inhibitory action of NPY on LH secretion. This finding strongly reinforces the concept that the Y5 receptor subtype is mainly, if not exclusively, involved in the NPY inhibitory action on LH secretion.
The Y5 receptor subtype was originally described as a receptor subtype mediating the orexigenic effect of NPY (25) . Our data with Y5 agonists and a specific Y5 antagonist confirmed that the Y5 receptor subtype is involved in the stimulation of food intake by exogenous NPY. The dose-response studies indicated that the Y5 agonist PYY was as potent as NPY, confirming the work of Gerald et al. (25) . Another Y5 agonist, hPP, was found to be as potent as [Leu 31 ,Pro 34 ]NPY in stimulating food intake. Finally, the Y5 antagonist that was used in the present study clearly blocked NPY-induced stimulation of food intake in the castrated rat. ]NPY, a weak but specific Y5 ligand (25, 27, 29) , that was found to be an agonist in our LH assay was unable to significantly induce food intake at 7 nmol, the highest dose used in the present study. In another study, central administration of ]NPY at a dose of 2 nmol stimulated food intake in rats (25 50 for the binding to receptors expressed on cell lines is strong for the Y5, weak for the Y1, and nonsignificant for the Y2 and Y4 subtypes (40) . Repeated icv injections of Y5 antisense oligodeoxynucleotides prevented both NPY-induced and fasting-induced food intake in rats (41) . NPY Y1 receptor-deficient mice have normal food intake and exhibit modest obesity and hyperinsulinemia (43) . Finally, Wieland et al. demonstrated that the Y1 receptor subtype is still involved in the stimulation of food intake by injecting the Y1 antagonist BIBO3304 (30 g/rat) locally at the level of the paraventricular nucleus that in these conditions could inhibit both the feeding response induced by 1 g NPY as well as the hyperphagia induced by a 24-h fast (36) . Obviously, more work is necessary to delineate the Y receptor subtype(s) for the action of NPY on feeding, but this was not the primary aim of the current study.
Much work is also still needed to understand the role of NPY in the modulation of gonadotropin secretion in physiological conditions, its role as an excitatory signal to LH release (31) , and its role to clarify the involvement of NPY action on that axis in several pathophysiological situations. The demonstration that null mutation of the NPY gene produced transgenic mice that were almost normal, with normal fertility, clearly cast some doubts on the relevance of the described specific stimulatory and inhibitory actions of NPY, in particular on reproduction (44, 45) . It is quite likely, however, that the important redundancy of peptides from the PP family and NPY receptor subtypes made possible a rapid reprogramming of the actions normally assigned to NPY, and then knockout mice appear normal at birth and in adulthood. Recently, similar findings were published with gene deletion of the Y1 receptor subtype (43, 46) and the Y5 receptor subtype (47) with, as an outcome, fertile mice. One important limitation of these studies is that NPY or specific NPY receptor are lost from conception, allowing the development of compensatory systems that could take the place of the missing NPY receptor. Development of useful induc-ible promoters will be an important advance for these transgene techniques.
The elegant studies by Kalra et al. have indicated that NPY is involved in the modulation of LH release at the time of the ovulatory peak, stressing the participation of NPY in the triggering of a large secretion of LH (31) . As important is the observation that NPY can inhibit LH/FSH secretion, at least when administered exogenously (21, 34) . There are several presumptions that endogenously produced NPY can also modulate gonadotropin secretion in pathological conditions (33, 48) . Gene expression for NPY and the synthesis and release of this peptide are enhanced in several pathological situations associated with hypogonadism, such as malnutrition (49), obesity (50) , and diabetes (51, 52) . Increased NPY output in the hypothalamus, such as that seen in diabetic rats that drives robust food intake (52), could also fulfill an inhibitory action on LH secretion. The recent demonstration that leptin administration to ob/ob mice reestablished LH secretion and fertility with a concomitant decrease in gene expression for NPY in the hypothalamus at least indicates that such a specific inhibitory action of NPY on gonadotropin secretion is possible (53) .
In conclusion, our results indicate that the Y5 receptor subtype is involved in the inhibitory control of the gonadotropic axis by NPY and confirm other work that have considered this subtype as a mediator of NPY action on food consumption.
